ASCO 2023 | Prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging

Ravi Madan, MD, National Cancer Institute, Bethesda, MD, discusses a recently launched trial (NCT05588128) at the National Cancer Institute, aiming to prospectively monitor patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL). Traditionally, these patients have been treated with androgen deprivation therapy (ADT) or chemotherapy based on imaging findings, which might not accurately reflect disease severity. The trial aims to monitor patients without immediate intervention to understand the natural history of early recurrent prostate cancer and determine if many of them can forgo unnecessary therapy. The trial will gather data on patients with recurrent disease and monitor them for up to five years, while also collecting biomarkers to better understand disease progression and identify clinically relevant cases. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.